Development
Vera Therapeutics, Inc.
VERA
$20.64
$0.190.93%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 29.80% | 43.96% | 61.50% | 83.84% | 104.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.89% | 100.40% | 125.11% | 164.24% | 25.70% |
| Operating Income | -46.89% | -100.40% | -125.11% | -164.24% | -25.70% |
| Income Before Tax | -39.90% | -90.35% | -126.86% | -173.11% | -25.29% |
| Income Tax Expenses | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Earnings from Continuing Operations | -39.90% | -90.35% | -126.86% | -173.10% | -25.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.90% | -90.35% | -126.86% | -173.10% | -25.29% |
| EBIT | -46.89% | -100.40% | -125.11% | -164.24% | -25.70% |
| EBITDA | 54.56% | -5.25% | -58.48% | -165.29% | -25.98% |
| EPS Basic | 2.56% | -38.57% | -56.88% | 75.71% | 98.04% |
| Normalized Basic EPS | 1.32% | -41.08% | -43.57% | 76.28% | 97.99% |
| EPS Diluted | 2.56% | -38.57% | -56.88% | 75.71% | 98.04% |
| Normalized Diluted EPS | 1.32% | -41.08% | -43.57% | 76.28% | 97.99% |
| Average Basic Shares Outstanding | 54.34% | 45.86% | 54.90% | 98.87% | 207.43% |
| Average Diluted Shares Outstanding | 54.34% | 45.86% | 54.90% | 98.87% | 207.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |